FGFR2-amplified gastric cancer cell lines require FGFR2 and Erbb3 signaling for growth and survival.

We have identified a critical role for amplified FGFR2 in gastric cancer cell proliferation and survival. In a panel of gastric cancer cell lines, fibroblast growth factor receptor 2 (FGFR2) was overexpressed and tyrosine phosphorylated selectively in FGFR2-amplified cell lines KatoIII, Snu16, and OCUM-2M. FGFR2 kinase inhibition by a specific small-molecule inhibitor resulted in selective and potent growth inhibition in FGFR2-amplified cell lines, resulting in growth arrest in KatoIII cells and prominent induction of apoptosis in both Snu16 and OCUM-2M cells. FGFR2-amplified cell lines also contained elevated phosphotyrosine in EGFR, Her2, and Erbb3, but the elevated phosphorylation in EGFR could not be inhibited by gefitinib or erlotinib. We show that the elevated EGFR, Her2, and Erbb3 phosphotyrosine is dependent on FGFR2, revealing EGFR family kinases to be downstream targets of amplified FGFR2. Moreover, shRNA to Erbb3 resulted in a loss of proliferation, confirming a functional role for the activated EGFR signaling pathway. These results reveal that both the FGFR2 and EGFR family signaling pathways are activated in FGFR2-amplified gastric cancer cell lines to drive cell proliferation and survival. Inhibitors of FGFR2 or Erbb3 signaling may have therapeutic efficacy in the subset of gastric cancers containing FGFR2 amplification.

[1]  C. McConkey,et al.  Cancer of the stomach. , 1989 .

[2]  J. Thiery,et al.  Inhibition of human bladder tumour cell growth by fibroblast growth factor receptor 2b is independent of its kinase activity. Involvement of the carboxy-terminal region of the receptor , 2004, Oncogene.

[3]  M. Yashiro,et al.  A novel molecular targeting compound as K-samII/FGF-R2 phosphorylation inhibitor, Ki23057, for Scirrhous gastric cancer. , 2006, Gastroenterology.

[4]  K. Yanagihara,et al.  Amplification of c-myc, K-sam, and c-met in gastric cancers: detection by fluorescence in situ hybridization. , 1998, Laboratory investigation; a journal of technical methods and pathology.

[5]  S. Hubbard,et al.  Crystal structure of an angiogenesis inhibitor bound to the FGF receptor tyrosine kinase domain , 1998, The EMBO journal.

[6]  A. Axon,et al.  Symptoms and diagnosis of gastric cancer at early curable stage. , 2006, Best practice & research. Clinical gastroenterology.

[7]  Jae-Hyun Park,et al.  Mutational analysis of BRAF and K-ras in gastric cancers: absence of BRAF mutations in gastric cancers , 2003, Human Genetics.

[8]  D. Amadori,et al.  DNA amplification in human gastric carcinomas. , 1993, Cancer genetics and cytogenetics.

[9]  P. P. Di Fiore,et al.  Therapy of an animal model of human gastric cancer using a combination of anti-erbB-2 monoclonal antibodies. , 1992, Cancer research.

[10]  M. Yashiro,et al.  K-ras mutation influences macroscopic features of gastric carcinoma. , 2005, The Journal of surgical research.

[11]  M. Ladanyi,et al.  Gene amplification in gastric and esophageal adenocarcinomas. , 1990, Cancer research.

[12]  P. Leder,et al.  Keratinocyte growth factor induces mammary and prostatic hyperplasia and mammary adenocarcinoma in transgenic mice. , 1996, Oncogene.

[13]  Z. Halpern,et al.  Activation of c-K-ras mutations in human gastrointestinal tumors. , 2000, Gastroenterology.

[14]  J. G. Park,et al.  Mutations in fibroblast growth factor receptor 2 and fibroblast growth factor receptor 3 genes associated with human gastric and colorectal cancers. , 2001, Cancer research.

[15]  Tom Misteli,et al.  Conservation of Relative Chromosome Positioning in Normal and Cancer Cells , 2002, Current Biology.

[16]  W. Ahn,et al.  ras Gene mutations and expression of Ras signal transduction mediators in gastric adenocarcinomas. , 2002, Archives of pathology & laboratory medicine.

[17]  G. Hager,et al.  Ligand-Specific Dynamics of the Androgen Receptor at Its Response Element in Living Cells , 2007, Molecular and Cellular Biology.

[18]  H. Ito,et al.  Frequent amplification of the c-met gene in scirrhous type stomach cancer. , 1992, Biochemical and biophysical research communications.

[19]  Gayatry Mohapatra,et al.  Amplification of MET may identify a subset of cancers with extreme sensitivity to the selective tyrosine kinase inhibitor PHA-665752 , 2006, Proceedings of the National Academy of Sciences of the United States of America.

[20]  N. Kohl,et al.  Lung cancer cell lines harboring MET gene amplification are dependent on Met for growth and survival. , 2007, Cancer research.

[21]  H. Sakamoto,et al.  Amplified genes in cancer in upper digestive tract. , 1993, Seminars in cancer biology.

[22]  A. Hagiwara,et al.  Amplification of growth factor receptor genes and DNA ploidy pattern in the progression of gastric cancer , 1997, Virchows Archiv.

[23]  Teruhiko Yoshida,et al.  K-sam, an amplified gene in stomach cancer, is a member of the heparin-binding growth factor receptor genes. , 1990, Proceedings of the National Academy of Sciences of the United States of America.

[24]  N. Nomura,et al.  Genetic alterations of the c-erbB-2 oncogene occur frequently in tubular adenocarcinoma of the stomach and are often accompanied by amplification of the v-erbA homologue. , 1988, Oncogene.

[25]  H. Höfler,et al.  E-cadherin gene mutations provide clues to diffuse type gastric carcinomas. , 1994, Cancer research.

[26]  K. Yanagihara,et al.  Preclinical study of a “tailor‐made” combination of NK4‐expressing gene therapy and gefitinib (ZD1839, Iressa™) for disseminated peritoneal scirrhous gastric cancer , 2006, International journal of cancer.

[27]  Sue Malcolm,et al.  Mutations in the fibroblast growth factor receptor 2 gene cause Crouzon syndrome , 1994, Nature Genetics.

[28]  N. Saijo,et al.  AZD2171 Shows Potent Antitumor Activity Against Gastric Cancer Over-Expressing Fibroblast Growth Factor Receptor 2/Keratinocyte Growth Factor Receptor , 2007, Clinical Cancer Research.

[29]  M. Makuuchi,et al.  Deletion of the carboxyl-terminal exons of K-sam/FGFR2 by short homology-mediated recombination, generating preferential expression of specific messenger RNAs. , 1999, Cancer research.

[30]  M. Inoue,et al.  Epidemiology of gastric cancer in Japan , 2005, Postgraduate Medical Journal.

[31]  N. Hanna,et al.  MET Amplification Leads to Gefitinib Resistance in Lung Cancer by Activating ERBB3 Signaling , 2008 .

[32]  J S Lee,et al.  Clinicopathologic significance of the K‐ras gene codon 12 point mutation in stomach cancer. An analysis of 140 cases , 1995, Cancer.

[33]  K. Shokat,et al.  Escape from HER family tyrosine kinase inhibitor therapy by the kinase inactive HER3 , 2007, Nature.

[34]  S. Kitano,et al.  Suppression of tumor growth in human gastric cancer with HER2 overexpression by an anti-HER2 antibody in a murine model. , 2005, International journal of oncology.

[35]  A. Axon,et al.  Why does Japan have a high incidence of gastric cancer? Comparison of gastritis between UK and Japanese patients , 2006, Gut.

[36]  J. Yokota,et al.  Isolation of an Amplified DNA Sequence in Stomach Cancer , 1990, Japanese journal of cancer research : Gann.

[37]  Shaun K Olsen,et al.  Receptor Specificity of the Fibroblast Growth Factor Family , 2006, Journal of Biological Chemistry.

[38]  K. Kunii,et al.  FGFR 2-Amplified Gastric Cancer Cell Lines Require FGFR 2 and Erbb 3 Signaling for Growth and Survival , 2008 .

[39]  R. Kratzke,et al.  ERBB2 amplifications in esophageal adenocarcinoma. , 2004, The Annals of thoracic surgery.

[40]  P. Laurén,et al.  THE TWO HISTOLOGICAL MAIN TYPES OF GASTRIC CARCINOMA: DIFFUSE AND SO-CALLED INTESTINAL-TYPE CARCINOMA. AN ATTEMPT AT A HISTO-CLINICAL CLASSIFICATION. , 1965, Acta pathologica et microbiologica Scandinavica.

[41]  A. Neugut,et al.  Epidemiology of gastric cancer. , 2006, World journal of gastroenterology.

[42]  J. Chmiel,et al.  Cancer of the stomach. A patient care study by the American College of Surgeons. , 1993, Annals of surgery.